Results from the KarMMa clinical trial: Secondary Quality-of-Life domains in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with the BCMA-directed CAR T cell therapy Idecabtagene Vicleucel (ide-cel; bb2121)
BLOOD（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要